The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

November 30, 2024

Conditions
SchizophreniaMyelin DegenerationCognition Disorder
Interventions
DRUG

Aripiprazole

Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.

Trial Locations (1)

20100

Prof. Paolo Brambilla, Milan

All Listed Sponsors
lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER